|
000
| 02029nam 2200361zi 4500 |
|---|
| 001 | 9.936452 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20240823104030 |
|---|
| 006 | m o d f |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 240408e202405 onc o f000 0 eng d |
|---|
| 020 | |a9780660712284 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH164-273/2024E-PDF |
|---|
| 245 | 00|aGuidance document : |bregulatory requirements for drug identification numbers (DINs). |
|---|
| 250 | |a[2024/05/01 edition]. |
|---|
| 264 | 1|aOttawa, Ontario : |bHealth Canada = Santé Canada, |cMay 2024. |
|---|
| 264 | 4|c©2024 |
|---|
| 300 | |a1 online resource (33 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aCover title. |
|---|
| 500 | |a"Administrative changes date: 2024/05/01." |
|---|
| 500 | |aIssued also in French under title: Ligne directrice : exigences réglementaires associées à une identification numérique attribuée à une drogue (DIN). |
|---|
| 520 | |a"When Health Canada authorizes a drug to be marketed in Canada, a Drug Identification Number (DIN) is issued to the manufacturer and printed on the package labels. A DIN indicates that the evaluation of the drug determined that it met the relevant requirements of the Food and Drugs Act and its Regulations and the drug has a favourable risk/benefit profile. Manufacturers of prescription and non-prescription drugs must obtain a DIN before they are marketed in Canada. Market authorization of a drug may require the additional issuance of a Notice of Compliance (NOC)"--Introduction, page 9. |
|---|
| 650 | 0|aDrugs|xLabeling|zCanada. |
|---|
| 710 | 1 |aCanada. |bHealth Canada, |eissuing body. |
|---|
| 775 | 08|tLigne directrice : |w(CaOODSP)9.936453 |
|---|
| 794 | |tGuidance document : |b[2024/07/15 edition]|w(CaOODSP)9.939764 |
|---|
| 795 | |tGuidance document : |b[2021/06/28 edition]|w9.899686 |
|---|
| 856 | 40|qPDF|s500 KB|uhttps://publications.gc.ca/collections/collection_2024/sc-hc/H164-273-2024-eng.pdf |
|---|